Literature DB >> 9237797

Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines.

M Polanski1, N S Melican, J Zhang, H L Weiner.   

Abstract

Oral administration of antigen leads to systemic immune unresponsiveness. Low dose oral tolerance generates regulatory cells which, when triggered in an antigen-specific manner, suppress inflammatory responses. We have previously shown that oral administration of an organ-specific antigen, porcine insulin, protects against diabetes development in the NOD mouse. In the present study we extend these observations to the B-chain of insulin, a 30-amino-acid peptide which has now been shown by others to contain the immunogenic epitope. Oral administration of the B-chain slowed diabetes development in a co-transfer model in which cells from B-chain-fed animals were co-transferred with diabetogenic cells (P=0.02). Further exposure to antigen via feeding of the co-transfer recipient animals not only slowed diabetes development but prevented diabetes in some animals (P=0.01). In vitro proliferation of popliteal lymph node cells from fed and immunized animals was suppressed in an antigen-specific manner when cells were restimulated with the fed antigen. When those cells were cultured and restimulated in vitro with the B-chain of insulin, we also observed a decrease in IFN-gamma expression and an increase in IL-4, TGF-beta and IL-10 expression. These results demonstrate that an orally protective epitope resides in the B-chain of insulin and that refeeding following adoptive transfer enhances protection. Finally, the orally administered antigen is associated with a decrease in Th1 responses and an increase in Th2 responses to the insulin B-chain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237797     DOI: 10.1006/jaut.1997.0148

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  27 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?

Authors:  K Honey; S P Cobbold; H Waldmann
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 3.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Overview of prevention and intervention trials for type 1 diabetes.

Authors:  Jorge Daaboul; Desmond Schatz
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

5.  Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin.

Authors:  L Monetini; M G Cavallo; E Sarugeri; F Sentinelli; L Stefanini; E Bosi; R Thorpe; P Pozzilli
Journal:  Diabetologia       Date:  2004-10-22       Impact factor: 10.122

6.  Expression of cholera toxin B subunit and the B chain of human insulin as a fusion protein in transgenic tobacco plants.

Authors:  Dora Li; Jennifer O'Leary; Yan Huang; Norman P A Huner; Anthony M Jevnikar; Shengwu Ma
Journal:  Plant Cell Rep       Date:  2005-12-02       Impact factor: 4.570

Review 7.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2018-08-30       Impact factor: 4.810

9.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

10.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.